Skip to content

Free cash flow at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$757M-55.3%
PTC Therapeutics logo
PTC TherapeuticsPTCT
-$60.24M-107%
Catalyst Pharmaceutical logo
Catalyst PharmaceuticalCPRX
$59.56M-0.8%
Dyne Therapeutics, Inc. logo
Dyne Therapeutics, Inc.DYN
-$145.14M-35.8%
Scholar Rock logo
Scholar RockSRRK
-$82.17M-4.1%
Cytokinetics logo
CytokineticsCYTK

Other financials

Income statement

See full
Operating income-$54.1M-17.7%
Net income-$49.0M-20.1%
EPS (diluted)-$0.46-7.0%

Balance sheet

See full
Cash & equivalents$33.2M-33.5%
Total debt$3.8M-16.8%
Total equity$493.2M+14.8%
Total assets$518.5M+14.1%

Cash flow

See full
Operating cash flow-$42.5M-12.4%
CapEx$260.0K+491%

Valuation

See full
Market cap$3.96B+61.3%
Enterprise value$3.93B+63.5%

Returns & leverage

See full
Return on equity-38.1%+13.4pp
Debt / equity0.0×
Current ratio22.6×+1.6×

Where this comes from

Calculated from Edgewise Therapeutics, Inc.’s reported figures.

The official record: Edgewise Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Edgewise Therapeutics, Inc.'s free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Edgewise Therapeutics, Inc.'s free cash flow?
Edgewise Therapeutics, Inc. (EWTX) reported free cash flow of -$42.8M in Q1 2026.
How has Edgewise Therapeutics, Inc.'s free cash flow changed year-over-year?
Edgewise Therapeutics, Inc.'s free cash flow decreased by 12.9% year-over-year, from -$37.91M to -$42.8M.
What is the long-term trend for Edgewise Therapeutics, Inc.'s free cash flow?
Over 4 years (2021 to 2025), Edgewise Therapeutics, Inc.'s free cash flow has grown at a 43.3% compound annual growth rate (CAGR), from -$34.18M to -$144.07M.
What does free cash flow mean?
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.